Safety, Tolerability and Immunogenicity of a Booster Dose of ZOSTAVAX Administered ≥10 Years After a First Dose Compared With a First Dose of ZOSTAVAX [EXTENSION OF 700006658]

Trial Profile

Safety, Tolerability and Immunogenicity of a Booster Dose of ZOSTAVAX Administered ≥10 Years After a First Dose Compared With a First Dose of ZOSTAVAX [EXTENSION OF 700006658]

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary)
  • Indications Varicella zoster virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 24 Mar 2016 Primary end points has been modified.
    • 16 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Feb 2015 Planned End Date changed from 1 May 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top